Zydus Lifesciences said that it has received final approval from the United States Food and Drug Administration (US FDA) to manufacture Apalutamide tablets, 60 mg.

Zydus Lifesciences, the Ahmedabad-based pharma giant, has started the intraday trade on Wednesday, March 19, on a positive note. This spurt in the share prices in the early session is a result of ...

Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive ...

But a new study has found that only one in 10 treatments for lower back pain are effective, with those that improve symptoms ...

Thanks to an enterprising group of Canadian college students, you may soon be able to grow your own GLP-1 drugs.

Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results on disease activity and IgG reduction.

The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium.  Arbli, an angiotensin II receptor ...

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment ...

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg (Erleada Tablets, 60 mg).

FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to-severe Sjögren’s disease, which could be the first targeted therapy ever ...

A novel therapeutic showed significant promise in slowing aortic valve calcification, potentially extending time until or eliminating need for transcatheter or surgical intervention for stenosis, ...

Zydus Lifesciences Ltd has received USFDA approval to manufacture a generic version of Apalutamide tablets for prostate cancer treatment. The 60 mg tablets will be produced in Ahmedabad, addressing a ...